[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550944":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":33,"responsibleParty":72,"collaborators":31,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":76,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":31,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":36,"whyStopped":31,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"ITB-Med LLC","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment","EXPERIMENTAL","TCD601 (siplizumab) administered with the contemporary standard of care regimen.",[13],"Biological: TCD601",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","TCD601","Investigational Product",[9],[21],"siplizumab",[23],{"name":24,"affiliation":5,"role":25},"Fredrik Julin","STUDY_DIRECTOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Fredrik Juhlin","CONTACT","+46 (0)76 394 9872",null,"fredrik.juhlin@itb-med.com",[34,50,61],{"facility":35,"status":36,"city":37,"state":31,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Skåne University Hospital Malmö","RECRUITING","Malmö","205 02","Sweden","SE",{"type":42,"coordinates":43},"Point",[44,45],13.00073,55.60587,{"lat":45,"lon":44},[48],{"name":49,"role":29,"phone":31,"phoneExt":31,"email":31},"Research Coordinator",{"facility":51,"status":36,"city":52,"state":31,"zip":53,"country":39,"countryCode":40,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Studieenheten Akademiskt Specialistcentrum","Stockholm","171 77",{"type":42,"coordinates":55},[56,57],18.06871,59.32938,{"lat":57,"lon":56},[60],{"name":49,"role":29,"phone":31,"phoneExt":31,"email":31},{"facility":62,"status":36,"city":63,"state":31,"zip":64,"country":39,"countryCode":40,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Umeå University Hospital","Umeå","901 85",{"type":42,"coordinates":66},[67,68],20.25972,63.82842,{"lat":68,"lon":67},[71],{"name":49,"role":29,"phone":31,"phoneExt":31,"email":31},{"type":73,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100550944","phase-1-a-study-of-tcd601-siplizumab-in-newly-diagnosed-adult-amyotrophic-lateral-sclerosis-als-patients-100550944",false,"NCT06453668","A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients","A 52-week, Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Trial of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (AURORA)","AURORA","Key Inclusion Criteria:\n\n* Male or female patients ≥ 18 to 80 years of age.\n* Diagnosis of ALS by revised El Escorial Criteria, at study entry within 24 months of first symptoms.\n* Patients on existing ALS treatment must have been on a stable dose for 28 days.\n\nKey Exclusion Criteria:\n\n* Patient with severe systemic infections, current or within the two weeks prior to randomization.\n* Subjects who, in the opinion of the investigator, are not capable of giving informed consent for the study or who are unable or unwilling to adhere to the study requirements outlined in the protocol.\n* Use of other investigational products or treatment in another investigational drug study within 30 days of screening\n* Pregnant or nursing (lactating) women.","ALL","18 Years","80 Years",{"count":86,"type":87},48,"ESTIMATED","INTERVENTIONAL",[90],"PHASE1","The purpose of this study is to investigate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TCD601 (siplizumab) in newly diagnosed adult ALS patients.",[93],"ALS",[95,96],"Amyotrophic Lateral Sclerosis","Neuroinflammatory","2026-03-25",{"date":99,"type":100},"2026-03-31","ACTUAL",{"date":102,"type":100},"2024-04-16",{"date":104,"type":87},"2029-11",{"name":5,"class":6},3]